Food and Drug Administration (FDA) approves drug, sold in the US under the brand name Leqembi – Concerns about its safety
The United States became the first country in the world to approve the drug for Alzheimer’s disease, lecanemabwhich appears to slow disease symptoms by 27% over an 18-month period.
The Food and Drug Administration (FDA) has approved the drug, which is sold in the US under the brand name Leqembi. The drug was developed by the pharmaceutical companies Biogen and Eisai.
Some experts believe that the drug changes the data in the treatment of Alzheimer’s, while there are not many options available to slow the disease anyway.
However, some other scientists question the drug’s effectiveness, and concerns have been raised about its safety. after the death of three patients in clinical trials.
Alzheimer’s disease is a chronic degenerative disease of the brain and is the most common cause of dementia. Its main clinical manifestation is memory impairment, but other brain functions are also affected and thus the patient’s social life is seriously affected.
Read the News today and get the latest news.
Follow Skai.gr on Google News and be the first to know all the news.
I have worked in the news industry for over 10 years. I have a vast amount of experience in covering health news. I am also an author at News Bulletin 247. I am highly experienced and knowledgeable in this field. I am a hard worker and always deliver quality work. I am a reliable source of information and always provide accurate information.
_164327.jpg?fit=%2C&ssl=1)
